Racotumomab Therapeutic Vaccine in the Treatment of Advanced Lung Cancer in the Elderly: A Case Report

We reported a clinical case of an 84-year-old smoker who was diagnosed with stage IV lung cancer and was included in the phase III clinical trial and treated with racotumomab. The patient had a an ECOG grade 0 according to the function scale. Therefore, it should be emphasized that this vaccine can improve the survival rate of patients with recurrent or advanced non-small cell lung cancer.
Martínez Feria F, Acosta Brooks SC, Cobián Caballero CO, 2015, Supervivencia libre de progresión de cáncer pulmonar de células no pequeñas en pacientes vacunados con CIMAvax-EGF [Progression-Free Survival of Non-small Cell Lung Cancer in Patients Vaccinated with CIMAvax-EGF]. Medisan, 19:1485–91.
Zalduendo P, 2016, Cáncer de pulmón. Síntomas, tipos, tratamiento y esperanza de vida [Lung Cancer: Symptoms, Types, Treatment and Life Expectancy]. Available from: https://www.enfermedadesgraves.com/blog/cancer-de-pulmon/.
De la Luz-Hernandez K, Rabasa Y, Montesinos R, et al., 2014, Cancer Vaccine Characteristics: From Bench to Clinic. Vaccines, 32:2851–8.
Noriega L, Bares JP, García E, et al., 2017, Factores de Riesgo y Tamizaje del Cáncer de Pulmón de Células No Pequeñas (CPCNP): 2do Consenso Nacional de la Sociedad Panameña de Oncología (Mesa 1) [Risk Factors and Screening of Non-small Cell Lung Cancer: Second National Consensus of the Panamanian Society of Oncology (Table 1)]. Rev Med Panamá, 37:2412–642X.
Wang Q, Huang H, Zeng X, et al., 2016, Single-Agent Maintenance Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Bayesian Network Meta-Analysis of 26 Randomized Controlled Trials. Peer J, 4:e2550.
Pérez Escobar MM, García Rodríguez ME, Armas Moredo K, et al., 2017, Cáncer de pulmón de células no pequeñas: presentación de caso [Non-Small Cell Lung Cancer: Case Report]. AMC, 21:258–63.
Gabri MR, Cacciavillano W, Chantada GL, et al., 2016, Racotumomab for Treating Lung Cancer and Pediatric Refractory Malignancies. Expert OpinBiol Ther, 16:573–8.
Maemondo M, Inoue A, Kobayashi K, et al., 2010, Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med, 362:2380–8.
Cobián Caballero CO, Acosta Brooks SC, Martínez Feria F, et al., 2016, Supervivencia en pacientes con cáncer pulmonar de células no pequeñas vacunados con CIMAvax-EGF [Survival Rate of Patients With Non-Small Cell Lung Cancer Inoculated sith CIMAvax-EGF]. MEDISAN, 20:320–8.
Hernández AM, Rodríguez N, González JE, et al., 2011, Anti-NeuGcGM3 Antibodies, Actively Elicited by Idiotypic Vaccination in Nonsmall Cell Lung Cancer Patients, Induce Tumor Cell Death by an Oncosis-Like Mechanism. J Immunol, 186:3735–44.